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Cytochromes P450 located in the endoplasmic reticulum require NADPH cytochrome 
P450 oxidoreductase (POR) for their catalytic activities. Mutations in POR cause multiple 
disorders in humans related to the biosynthesis of steroid hormones and also affect drug-
metabolizing cytochrome P450 activities. Electron transfer in POR occurs from NADH to 
FAD to FMN, and the flexible hinge region in POR is essential for domain movements 
to bring the FAD and FMN close together for electron transfer. We tested the effect of 
variations in the hinge region of POR to check if the effects would be similar across all 
redox partners or there will be differences in activities. Here we are reporting the effects 
of a POR genetic variant P284T located in the hinge region of POR that is necessary 
for the domain movements and internal electron transfer between co-factors. Human 
wild-type and P284T mutant of POR and cytochrome P450 proteins were expressed 
in bacteria, purified, and reconstituted for enzyme assays. We found that for the P284T 
variant of POR, the cytochrome c reduction activity was reduced to 47% of the WT and 
MTT reduction was reduced to only 15% of the WT. No impact on ferricyanide reduction 
activity was observed, indicating intact direct electron transfer from FAD to ferricyanide, but 
a severe loss of CYP19A1 (aromatase) activity was observed (9% of WT). In the assays of 
drug-metabolizing cytochrome P450 enzymes, the P284T variant of POR showed 26% 
activity for CYP2C9, 44% activity for CYP2C19, 23% activity for CYP3A4, and 44% activity 
in CYP3A5 assays compared to the WT POR. These results indicate a severe effect on 
several cytochrome P450 activities due to the P284T variation in POR, which suggests a 
negative impact on both the steroid as well as drug metabolism in the individuals carrying 
this variation. The negative impact of P284T mutation in the hinge region of POR seems to 
be due to disruption of FAD to FMN electron transfer. These results further emphasize the 
importance of hinge region in POR for protein flexibility and electron transfer within POR as 
well as the interaction of POR with different redox partners.
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INTRODUCTION
The NADPH cytochrome P450 reductase (POR, NCBI# 
NP_000932, UniProt# P16435) is required for the enzymatic 
activities for all human cytochromes P450 proteins located in 
the endoplasmic reticulum (Pandey and Flück, 2013; Flück and 
Pandey, 2019). Cytochrome P450 proteins metabolize a broad 
range of endogenous and exogenous chemicals, including 
most of the drugs, steroids and other xenobiotics (Schuster and 
Bernhardt, 2007; Omura, 2010; Zanger and Schwab, 2013). There 
are two different types of cytochrome P450 proteins in mammals 
(Omura, 2010; Mclean et al., 2015). The type 1 P450s are located 
in the mitochondria and use the adrenodoxin/adrenodoxin 
reductase system as their redox partner (Omura, 2006; Zalewski 
et al., 2016). The type 2 cytochrome P450s are located in the 
endoplasmic reticulum and use a single diflavin reductase, POR, as 
their redox partner (Lu et al., 1969; Masters, 2005). POR contains 
both the flavin mononucleotide (FMN) and the flavin adenine 
dinucleotide (FAD), which are bound to distinct domains, and 
supplies electrons to cytochromes P450 and other proteins via 
protein-protein interactions (Iyanagi and Mason, 1973; Iyanagi 
et al., 1974; Matsubara et al., 1976; Vermilion and Coon, 1978; 
Oprian and Coon, 1980; Narayanasami et al., 1992) (Figure 1). 
The three-dimensional structure of the FMN binding domain of 
human POR has been solved by x-ray crystallography (Zhao et al., 
1999) and more recently many structures of soluble POR proteins 
containing the NADPH, FAD, and FMN binding domains, but 
lacking the membrane-bound amino terminus sequence, have 
been determined by the groups of Kim and Masters (Wang et al., 
1997; Xia et al., 2011a; Xia et al., 2011b). The FMN and FAD/
NADPH binding domains of POR are connected by a flexible hinge 
region. The hinge region of POR is vital for domain movements 
within the POR protein and provides structural flexibility to bring 
the FAD and FMN domains together, in addition to influencing 
interactions with the redox partners of POR for electron transfer.
Human POR deficiency (PORD, OMIM: 613537 and 201750) 
is a form of congenital adrenal hyperplasia, initially described in 
patients with altered steroidogenesis reported by the laboratory 
of Walter Miller (Flück et al., 2004; Miller et al., 2004; Flück et al., 
2007; Flück and Pandey, 2011; Flück and Pandey, 2013; Pandey and 
Flück, 2013; Fukami and Ogata, 2014; Pandey and Sproll, 2014; 
Flück and Pandey, 2019) followed by several reports with a broad 
spectrum of disorders (Adachi et al., 2004; Arlt et al., 2004; Pandey 
and Flück, 2013; Flück and Pandey, 2014; Pandey and Sproll, 2014; 
Oldani et al., 2015; Bonamichi et al., 2016; Nakanishi et al., 2016; 
Burkhard et al., 2017; Flück and Pandey, 2019). Congenital adrenal 
hyperplasia is an inborn error of adrenal steroid biosynthesis 
affecting the production of glucocorticoids (Miller and Fluck, 2014; 
Fluck, 2017). Defects in multiple steroid metabolizing cytochrome 
P450 proteins were suggested by Cedric Shackleton from the 
analysis of steroid hormones in the urine of patients with signs 
of disordered steroid metabolism, but no genetic mutations were 
identified (Peterson et al., 1985). Sequencing of the POR gene in 
patients with symptoms of mixed oxidase deficiency revealed 
mutations in POR linked to disorders of steroid biosynthesis (Flück 
et al., 2004; Miller et al., 2004; Pandey et al., 2004). Afterward, several 
different laboratories reported mutations in POR in patients with 
steroid biosynthesis disorders and bone malformation syndromes 
(Adachi et al., 2004; Arlt et al., 2004; Fukami et al., 2005; Pandey 
and Flück, 2013; Riddick et al., 2013).
FIGURE 1 | POR as electron transfer partner to cytochromes P450 proteins. Transfer of electrons from NADPH to redox partners of POR. Co-factor NADPH 
binds to the POR located into the endoplasmic reticulum and donates electrons which are received by FAD. Electron transfer to FAD causes a conformational 
change in POR that brings together the FAD, and FMN domains and electrons are then transferred from FAD to FMN. The FMN domain of POR interacts with the 
P450s and other redox partners and completes the final step of electron transfer. From Pandey, A. V. and Sproll, P. (2014). “Pharmacogenomics of human P450 
oxidoreductase.” Frontiers in Pharmacology 5, 103.
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In addition to steroid metabolizing cytochrome P450 enzymes, 
POR is also the redox partner of multiple drug metabolizing 
cytochrome P450 enzymes, and therefore, a negative impact of 
POR mutations is expected on activities of all partner proteins. 
While the initial studies on mutations in POR were aimed at 
deducing the impact on metabolism of steroid hormones, effects 
of POR mutations on other redox partners, including heme 
oxygenase and drug-metabolizing cytochromes P450, have been 
studied in later reports (Marohnic et al., 2006; Agrawal et al., 2008a; 
Agrawal et al., 2010; Flück et al., 2010; Marohnic et al., 2010; 
Nicolo et al., 2010; Pandey et al., 2010; Marohnic et al., 2011; 
Mccammon et al., 2016; Udhane et al., 2017; Velazquez et al., 
2019). A mouse knockout (KO) model of Por-/- had been 
generated before the human mutations in POR were identified. 
The Por-/- was found to be embryonic lethal (Shen et al., 2002; 
Nicholas et al., 2017), and resembled the KO mouse model of 
retinoic acid-metabolizing Cyp26a1-/- (Gaston-Massuet et al., 
2016). Liver-specific deletion of POR has been reported to 
cause lipidosis and increased liver weight (Gu et al., 2003; Wu 
et al., 2003). Deletion of POR gene in cardiomyocyte cells of the 
mouse leads to reduced P450 activity in the heart, but there was 
no indication of embryonic lethality or early morbidity and no 
difference in heart function was observed (Fang et al., 2008). 
A summary of the impact of POR variations and effects of Por 
knockout/knockdown had been provided by Riddick, Ding, Wolf 
Porter, and Pandey (Riddick et al., 2013).
Large-scale sequencing projects have now identified 
many variations in the POR gene in several different human 
subpopulations, and multiple POR variants have been linked 
to altered drug metabolism (Huang, 2008 #758; Gomes et al., 
2009; Pandey, 2010 #579; Nicolo, 2010 #396; Agrawal, 2010 
#720; Gomes et al., 2009; Velazquez, 2019 #2260). Several 
variants in the POR gene found in patients as well as non-
clinical samples have been tested for enzymatic activities 
(Adachi et al., 2004; Arlt et al., 2004; Fukami et al., 2005; 
Fukami et al., 2006; Homma et al., 2006; Pandey, 2006; 
Huang et al., 2008a; Sim et al., 2009). While the mutations 
in POR could be located in all regions of the protein, based 
on analysis of previously identified mutations, some definite 
patterns have emerged. Mutations in POR that affect binding 
of co-factors (FMN/FAD/NADPH) cause a severe form of 
the disease with the mutations causing severe loss of FMN 
or FAD showing significant inhibitory effects on activities of 
all redox partners. We have previously shown that aromatase 
(CYP19A1) activity responsible for the metabolism of 
androgens is very susceptible to mutations in NADPH binding 
site of POR (Pandey et al., 2007; Flück et al., 2011; Flück and 
Pandey, 2017). On the other hand, mutations in POR affecting 
interaction with P450 and other redox partner are harder to 
predict since individual mutations may show different effects 
on individual partner enzymes.
While the mutations in the co-factor binding region of POR 
have clear mechanisms for loss of activities observed (explained 
by the reduction or loss of bound FAD or FMN), the mutations 
in the hinge region of POR require detailed characterization 
to understand the mechanisms of inactivation. While multiple 
mutations at or near the cofactor binding sites have been 
characterized in detail, mutations in the hinge region of POR have 
not received much attention. Considering the importance of the 
hinge region in the electron transfer process of the POR redox 
system, we looked at POR variants located in the flexible region 
of POR to understand the metabolic effects caused by mutations 
that may affect structural flexibility. In the current study, we have 
investigated the effects of POR variant P284T located near the 
hinge region of POR that is crucial for interactions with redox 
partner proteins, including P450s, to transfer electrons from 
NADPH. The POR variant P284T (rs72557937) was found in the 
Yoruba population through the sequencing of DNA obtained 
from a particular community in Ibadan, Nigeria (https://
www.coriell.org/0/Sections/Collections/NHGRI/Yoruba.aspx? 
PgId=128). Based on information available through the 1000 
genome project, the samples were from parent-adult child 
trios, and all parents in the trios had identified themselves as 
having four Yoruba grandparents. The P284T variant of POR 
was also found in the African American population in the POR 
sequencing study carried out by Miller (Huang et al., 2008b). 
Previously, in a study based on computational prediction, we have 
identified structurally destabilizing population genetic variants 
in POR (Burkhard et al., 2017). In the analysis by Burkhardt 
et al. changes at the amino acid 284 of POR were predicted to 
cause protein malfunction (Burkhard et al., 2017). Here, we 
have tested the hypothesis that mutations in the hinge region of 
POR may cause loss of enzymatic activities that may depend on 
interactions with redox partners. In the current study, we aimed 
to characterize different activities of POR that are affected by the 
mutation P284T in the hinge region and assayed several drug-
metabolizing cytochrome P450 enzymes, steroid metabolizing 
enzyme aromatase, and some direct reactions of POR like the 
reduction of small molecules. Our results confirmed that indeed, 
some reactions were unaffected by the P284T (Ferricyanide 
reduction activity), others had a range of effects from loss of 
75–80% activity in case of CYP2C9 and CYP3A4, to CYP2C19, 
CYP3A5, and cytochrome c reduction that were only mildly 
affected. Aromatase, which requires several interactions with 
POR to complete one reaction cycle, was severely affected, losing 
more than 90% of the activity compared to reaction supported 
by the WT POR. These results indicate the importance of the 
hinge region in POR in the interaction with redox partners and 
confirm that changes in the hinge region may have variable 
effects on POR activity depending on individual redox partners.
MATERIALS AND METHODS
Recombinant Expression of POR 
and Membrane Purification
The human POR WT and variant forms of proteins (NCBI# 
NP_000932, Uniprot# P16435) were recombinantly expressed in 
bacteria using the previously described methods and expression 
constructs (Huang et al., 2005; Pandey et al., 2007; Huang et al., 
2008a; Nicolo et al., 2010). The protocol for expression of an N-27 
form of POR variants and subsequent membrane purification 
have been adopted from our previous publications (Huang et al., 
2005; Pandey et al., 2007; Pandey et al., 2010; Parween et al., 2016; 
POR Mutation P284T and Cytochrome P450Parween et al.
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Flück and Pandey, 2017). The cDNAs for WT or mutant POR in a 
pET22b vector were transformed into Escherichia coli BL21(DE3). 
Single colonies were selected for growth on ampicillin and grown 
in terrific broth pH 7.4 supplemented with 40 mM FeCl3, 4 mM 
ZnCl2, 2 mM CoCl2, 2 mM Na2MoO4, 2 mM CaCl2, 2 mM CuCl2, 
2 mM H3BO3, 0.5 mg/ml riboflavin, 100 µg/ml carbenicillin at 
37°C to an optical density (OD) 600 nm of 0.6 and temperature 
was reduced to 25°C for 16 h. The bacterial cells were collected by 
centrifugation, washed with PBS and suspended in 100 mM Tris-
acetate (pH 7.6), 0.5 M sucrose, and 1 mM EDTA and treated with 
lysozyme (0.5 mg/ml) and EDTA [0.1 mM (pH 8.0)] at 4°C for 1 h 
with slow stirring to generate spheroplasts. The spheroplasts were 
pelleted by centrifugation at 5,000×g for 15 min; and suspended 
in 100 mM potassium phosphate (pH 7.6), 6 mM Magnesium 
acetate, 0.1 mM DTT, 20% (v/v) glycerol, 0.2 mM PMSF, and 0.1 
mM DNase I; and disrupted by sonication. A clear lysate devoid 
of cellular debris was obtained by centrifugation at 12,000×g for 
10 min, and then the membranes were collected by centrifugation 
at 100,000×g for 60 min at 4°C. Membranes containing POR were 
mixed in 50 mM Potassium phosphate buffer (pH 7.8) and 20% 
(v/v) glycerol and kept at −70ºC. The concentrations of proteins 
were measured by the RC-DC protein assay method (Protein 
Assay Dye Reagent, Bio-Rad, Hercules, CA) and POR content in 
membrane proteins was measured by western blot analysis.
Western Blot Analysis of POR Content 
in the Bacterial Membranes
For Western blots, 1 μg of POR-WT and POR-P284T bacterial 
membrane proteins were separated on an SDS-PAGE gel and 
blotted on to polyvinyl difluoride (PVDF) membranes. Blots were 
first incubated with a rabbit polyclonal antibody against wild-type 
human POR from Genscript (Genscript, NJ, USA) at a dilution 
of 1:1,000. We then used a secondary goat anti-rabbit antibody 
labeled with a phthalocyanine infrared dye (IRDye 700DX, 
LI-COR Bioscience Inc., NE, USA) at a 1:10,000 dilution. Signals 
were analyzed with the green fluorescent channel (700 nm) on 
an Odyssey Infrared Imaging System (LI-COR Bioscience Inc., 
NE, USA), and protein bands were measured using the Odyssey 
software (LI-COR Bioscience Inc., NE, USA). POR content of 
each membrane preparation was measured, and all samples were 
normalized against purified wild-type POR used as a standard. In 
all experiments described in this report, the normalized amount of 
POR content was used for the mutants as well as WT POR protein.
Small Molecule Reduction Assay by WT 
and POR-P284T
Assay of cytochrome c reduction by bacterially expressed WT or 
POR-284T was performed as described previously by measuring the 
change in absorbance at 550 nm (ε = 21.1 cm−1 mM−1) (Guengerich 
et al., 2009). In brief, the POR reduction reaction was performed 
in 96-well plates, in triplicate, with 5 µg membrane preparation 
containing POR in each well in 100 mM Tris-HCl (pH 7.5), using a 
microplate reader (Spectramax M2e, Molecular Devices, Sunnyvale, 
CA). The concentration of NADPH used was 100 µM and 
concentrations of cytochrome c (1.3–40 μM) were varied for kinetic 
analysis. The POR reduction reaction was initiated by the addition 
of NADPH, and the change in absorbance at 550 nm was monitored 
over 6 min. Data were fitted based on Michaelis-Menten kinetics 
(Michaelis and Menten, 1913) using GraphPad Prism (GraphPad 
Software, La Jolla, CA USA) to determine the Vmax and Km.
The NADPH-dependent MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium] reduction rate was measured as the rate 
of increase in absorbance at 610 nm using an extinction coefficient 
of ε610 = 11 mM-1 cm-1 (Yim et al., 2005). The assay mixture 
contained 5 µg of bacterial membranes containing POR in 100 mM 
phosphate buffer (pH 7.6), 100µM NADPH and concentration of 
MTT varied from 3.9-500 µM. Similarly, the ferricyanide reduction 
rate was measured as the rate of decrease in absorbance at 420 nm 
(ε420 = 1.02 mM-1 cm-1). The concentration of ferricyanide varied 
over a range from 3.9 to 500 µM, and the reactions were started 
by adding 100µM NADPH (Marohnic et al., 2010). Activities 
represent the mean of at least triplicate determinations.
Flavin Content Analysis of WT 
and Mutant POR
Protein-bound flavin molecules were released by thermal denaturation 
of POR proteins (Faeder and Siegel, 1973). Flavin content of WT and 
mutant POR proteins (100 µg/ml) was determined by boiling protein 
samples at 95°C for 10 min in the dark, followed by centrifugation at 
14,000 ×g for 10 min to remove coagulated protein. The FMN and 
FAD ratio was determined by measurement of fluorescence of the 
supernatant at pH 7.7 and pH 2.6 (excitation at 450 nm, emission at 
535 nm) (Faeder and Siegel, 1973).
Expression and Purification 
of Human CYP19A1
The vector for bacterial expression of human CYP19A1was 
transformed in E. coli BL21(DE3) cells and the recombinant 
protein was expressed and purified following previously published 
protocols (Kagawa et al., 2003; Kagawa, 2011), with slight 
modifications. Briefly, a single transformed colony was selected 
for protein expression at 25°C. After 4 h of incubation, 1 mM 
δ-aminolevulinic acid (a heme precursor) and 4 mg/ml arabinose 
(for induction of molecular chaperones GroEL/GroES) were added 
to the culture and further incubated for 20 h. Cells were harvested, 
and spheroplasts were prepared with 0.2 mg/ml lysozyme in 50 
mM Tris-Acetate (pH 7.6), 250 mM sucrose, and 0.5 mM EDTA 
at stored at -80°C. For protein purification, spheroplasts were lysed 
using 10XCellLytic B (Sigma-Aldrich) in buffer containing 100 mM 
potassium phosphate (pH 7.4), 500 mM sodium acetate, 0.1 mM 
EDTA, 0.1 mM DTT, 20% glycerol, and 1 mM PMSF. The cell lysate 
was centrifuged, and the supernatants were pooled for purification 
by Ni2+ affinity chromatography. Purification was performed at 
4°C and protein concentration after the dialysis was determined by 
DC protein assay (Protein Assay Dye Reagent, Bio-Rad, Hercules, 
CA) using BSA as standard.
Assay of Cytochrome P450 CYP19A1 
in Reconstituted Liposome System
Purified recombinant CYP19A1 using the bacterial expression 
system was used to test the effect of POR-284T to support the 
POR Mutation P284T and Cytochrome P450Parween et al.
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aromatase activity of CYP19A1. Standard tritiated water release 
assay for the CYP19A1 activity was performed in a reconstituted 
liposome system using androstenedione as a substrate. Bacterial 
membranes containing POR and purified CYP19A1 were 
reconstituted into DLPC-DLPG liposomes. The liposomes were 
prepared previously (Udhane et al., 2017), and aromatase activity 
was measured by the tritiated water release assay originally 
described by Lephart and Simpson (Lephart and Simpson, 
1991) using androstenedione as the substrate. Reaction mixture 
consisted of 100 pmol of CYP19A1, 400 pmol of POR, 100 mM 
NaCl and 3H labeled androstenedione ([1β-3H(N)]-andros-
tene-3,17-dione; ~20,000 cpm) in 100 mM potassium phosphate 
buffer (pH 7.4). Different concentrations (10–1000 nM) of 
androstenedione were used for kinetic analysis. The catalytic 
reaction was initiated by the addition of 1 mM NADPH, and the 
reaction tube was incubated for 1 h under shaking. Data were 
fitted based on Michaelis-Menten kinetics using GraphPad Prism 
(GraphPad Software, La Jolla, CA, USA).
Assay of Cytochrome P450 CYP2C9 
Activity in Reconstituted System
The activity of CYP2C9 promoted by WT or mutant POR was 
tested using the fluorogenic substrate BOMCC (Invitrogen 
Corp, Carlsbad, CA, USA). The purified CYP2C9 (CYPEX, 
Dundee, Scotland, United Kingdom) was used to test the 
activities of the POR variants using 20 µM BOMCC as 
substrate. In vitro CYP2C9 assays were performed using a 
reconstituted liposome system consisting of WT/mutant POR, 
CYP2C9, and cytochrome b5 at a ratio of 5:1:1. The final assay 
mixture consisted of 5 µg DLPC (1,2-Dilauroyl-sn-glycero-3-
phosphocholine) and proteins (1 µM POR: 200 nM CYP2C9: 
200 nM b5), 3 mM MgCl2, 20 µM BOMCC in 100 mM Tris-
HCl buffer PH 7.4, and the reaction volume was 100 µL. The 
P450 reaction was started by addition of NADPH to a final 
concentration of 1 mM, and fluorescence was measured on a 
Spectramax M2e plate reader (Molecular Devices, Sunnyvale, 
CA, USA) at an excitation wavelength of 415 nm and an 
emission wavelength of 460 nm for BOMCC.
Assay of Cytochrome P450 CYP2C19 
Activity in Reconstituted System
The activity of CYP2C19 promoted by WT or mutant POR was 
tested using the fluorogenic substrate EOMCC (Invitrogen 
Corp, Carlsbad, CA, USA). The purified CYP2C19 (CYPEX, 
Dundee, Scotland, UK) was used to test the activities of the POR 
variants using 20 µM EOMCC as substrate. In vitro CYP2C19 
assays were performed using a reconstituted liposome system 
consisting of WT/mutant POR, CYP2C9 and cytochrome b5 
at a ratio of 5:1:1. The final assay mixture consisted of 2.5 
µg DLPC (1,2-Dilauroyl-sn-glycero-3-phosphocholine) and 
proteins (0.5 µM POR: 100 nM CYP2C9: 100 nM b5), 3 mM 
MgCl2, 20 µM EOMCC in 100 mM Tris-HCl buffer PH 7.4 
and the reaction volume was 100 µL. The P450 reaction was 
started by addition of NADPH to a final concentration of 0.5 
mM, and fluorescence was measured on a Spectramax M2e 
plate reader (Molecular Devices, Sunnyvale, CA, USA) at an 
excitation wavelength of 415 nm and an emission wavelength 
of 460 nm for BOMCC.
Assay of Cytochrome P450 CYP3A4 
Activity in Reconstituted System
To compare the activities of CYP19A1 with another steroid-
binding cytochrome P450, we tested the ability of POR 
mutations to support the enzyme activity of CYP3A4. 
The activity of the drug-metabolizing enzyme CYP3A4 
supported by POR-WT or POR-284T was tested using 
the fluorogenic substrates BOMCC (7-Benzyloxy-4-
trifluoromethylcoumarin) (Invitrogen Corp, Carlsbad, CA) as 
described earlier (Flück et al., 2010). The purified CYP3A4 
(CYPEX, Dundee, Scotland, UK) was used to test the activities 
of the POR variants using 20 µM BOMCC. In-vitro CYP3A4 
assays were performed using a reconstituted liposome system 
consisting of WT/mutant POR, CYP3A4, and cytochrome b5 
at a ratio of 4:1:1 (POR : CYP3A4:b5). The final assay mixture 
consisted of liposomes and proteins (80 pmol POR: 20 pmol 
CYP3A4: 20 pmol b5), 2.5 mM MgCl2, 2.5 µM GSH and 20 µM 
BOMCC in 50 mM HEPES buffer and the reaction volume 
was 200 µl. The catalytic reaction was initiated by addition 
of NADPH to 1 mM final concentration, and fluorescence 
was monitored on a Spectramax M2e plate reader (Molecular 
Devices, Sunnyvale, CA) at an excitation wavelength of 415 
nm and an emission wavelength of 460 nm.
Assay of Cytochrome P450 CYP3A5 
Activity in Reconstituted System
The activity of CYP3A5 promoted by WT or mutant POR was 
tested using the fluorogenic substrate BOMCC (Invitrogen 
Corp, Carlsbad, CA, USA). The purified CYP3A5 (CYPEX, 
Dundee, Scotland, UK) was used to test the activities of 
the POR variants using 20 µM BOMCC as substrate. In 
vitro CYP3A5 assays were performed using a reconstituted 
liposome system consisting of WT/mutant POR, CYP3A5 
and cytochrome b5 at a ratio of 5:1:1. The final assay mixture 
consisted of 5 µg DLPC (1,2-Dilauroyl-sn-glycero-3-
phosphocholine) and proteins (1 µM POR: 200 nM CYP2C9: 
200 nM b5), 3 mM MgCl2, 20 µM BOMCC in 100 mM Tris-
HCl buffer PH 7.4, and the reaction volume was 100 µL. The 
CYP3A5 reaction was started by addition of NADPH to 1 
mM final concentration, and fluorescence was measured on a 
Spectramax M2e plate reader (Molecular Devices, Sunnyvale, 
CA, USA) at an excitation wavelength of 415 nm and an 
emission wavelength of 460 nm for BOMCC.
Statistical Analysis of Results
Data are shown as mean, standard errors of the mean (SEM) 
in each group or replicates. Differences within the subsets of 
experiments were calculated using Student’s t-test. P values less 
than 0.05 were considered statistically significant.
POR Mutation P284T and Cytochrome P450Parween et al.
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RESULTS
Effect of POR-P284T on Small Molecule 
Reduction Activity
To study the effect of the P284T mutation on POR activity, 
we expressed WT and POR-P284T in E. coli and prepared the 
membranes. Using the membrane preparations containing the 
enriched POR, we measured their ability to transfer electrons 
from NADPH to cytochrome c, MTT, or ferricyanide. The POR-
P284T mutation had a much lower capacity to reduce cytochrome 
c and MTT (Table 1, Figures 2A, B). Compared to WT POR, the 
P284T variant lost ~50% of its activity to reduce cytochrome c and 
had only 15% of the WT POR activity to reduce MTT. However, 
the ferricyanide reduction activity (Table 1, Figure 2C) was not 
affected by the P284T mutation. Kinetic and statistical analysis 
is summarized in Table 1. The loss of activities with cytochrome 
c and MTT indicates disruption of electron transport from 
FAD to FMN, which could be due to conformational instability 
due to a P284T mutation affecting domain movements as well 
as a chain reaction starting from the disruption of electron 
transfer from NADPH to FAD. To differentiate between the 
two mechanisms, we tested the reduction of ferricyanide that 
can be reduced directly through FAD. Since the ferricyanide 
reduction activity of POR-P284T was comparable to WT, it can 
be deduced that electron transfer from NADPH to the FAD is 
not affected.
The P284T Mutation in POR Causes 
a Reduction of Flavin Content
To differentiate the conformational changes and effects of POR 
mutation P284T on flavin binding, we evaluated the relative 
flavin content since the activity of POR may be affected by the 
changes in the binding of cofactors FMN and FAD. As compared 
to WT POR, both the FMN and the FAD-binding was affected 
due to P284T mutation. The FMN content of POR-P284T was 
64% as compared to WT, while the FAD content was reduced 
by 35%, suggesting that POR-P284T affects both FMN as well 
as FAD binding to POR (Figure 3). Differences compared to 
controls were calculated using Student’s t-test, and P values were 
below 0.01, indicating statistically significant differences. Since 
the residue P284 is not directly involved in either the FMN or the 
FAD-binding, a loss of flavins indicated a role of conformational 
changes caused by the P284T mutation to be responsible for 
the reduced flavin binding. The P284T mutation is, therefore, 
creating conformational changes that are less favorable for the 
binding of flavins in POR.
CYP19A1-Aromatase Activity
The CYP19A1 requires six pairs of electrons for one reaction 
cycle, compared to two for most P450s, and therefore is more 
susceptible to changes in protein-protein interactions that dictate 
the electron transfer between POR and its redox partners. The 
POR-P284T showed almost complete loss of CYP19A1 activity 
(Figure 4, Table 1). For the POR-P284T variant, the apparent 
Km for androstenedione was increased by 2-fold as compared 
to WT POR suggesting that P284T mutation affects either 
substrate interaction with CYP19A1 or the CYP19A1-POR 
interaction. The apparent Vmax of POR-P284T was reduced by 
~85%. The POR variant P284T showed only 9% residual activity 
in supporting CYP19A1 as compared to WT POR. Kinetic and 
statistical analysis is summarized in Table 1.
CYP2C9 Activity
We tested the activity of CYP2C9 supported by the WT and 
P284T variant of POR in reconstituted liposomes. Compared 
to WT POR activity of CYP2C19 supported by P284T variant 
of POR was reduced by 78% (Figure 5). This loss of more than 
three-quarters of activity compared to WT POR indicated 
a severe effect on drug metabolism supported by CYP2C9. 
TABLE 1 | Kinetic parameters for activities of cytochrome c, MTT, ferricyanide reduction, and CYP19A1 activity supported by POR-WT and POR-P284T variant. 
Km,
(µM)
Vmax
µmol/min/mg
Vmax/Km % WT
Cytochrome c reduction assay 
WT 4.6 ± 0.7 128.2 ± 6.1 27.6 100
P284T 3.7 ± 0.8 48.7 ± 3 13 47
MTT reduction assay 
WT 19.9 ± 1.8 179.5 ± 4 9 100
P284T 48.3 ± 7.5 64.8 ± 3.1 1.3 15
Ferricyanide reduction assay 
WT 18.9 ± 2.4 600 ± 19 31.8 100
P284T 6.9 ± 1.6 248.1 ± 11 36 113
Km, Androstenedione
(nM)
Vmax
pmol/min/nmol
Vmax/Km % WT
CYP19A1; aromatase (androstenedione to estrone)
WT 80 ± 14.5 0.72 ± 0.03 0.009 100
P284T 165.7 ± 147.9 0.12 ± 0.037 0.0008 9
For the cytochrome c, MTT and Ferricyanide reduction assay, the NADPH concentration was fixed at 100 µM and varying concentrations of the substrate were used for the analysis. 
For the conversion of androstenedione to estrone, NADPH was fixed at 1 mM, and variable concentrations (10–1000 nM) of androstenedione were used. Data are shown as mean ± 
SEM of independent replicates (n = 3 for cytochrome c, MTT and ferricyanide assay; n = 2 for CYP19A1 assay).
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Differences compared to controls were calculated using Student’s 
t-test, and P values were below 0.001, indicating statistically 
significant differences.
CYP2C19 Activity
The activity of CYP2C19 was tested with both the WT and P284T 
variant of POR. We found that in CYP2C19 assays, the P284T 
variant of POR showed only 44% of the WT POR activity with 
P values below 0.001 in Student’s t-test, indicating statistically 
significant differences (Figure 6). The effect of P284T variation in 
POR on CYP2C19 was not as strong as in case of CYP2C9 activity, 
but the loss of activity was still more than 50%, indicating a reduced 
capacity of drug metabolism reactions mediated by CYP2C19.
CYP3A4 Activity
The P284T variant of POR showed only 22.8% activity as compared 
to the WT enzyme with P values below 0.001 in Student’s t-test, 
indicating statistically significant differences (Figure 7). The loss 
of activities for drug-metabolizing cytochrome P450 enzyme-
CYP3A4 by the POR variant P284T indicates problems with 
POR-P450 interactions which seem to be different for different 
cytochrome P450 partners.
CYP3A5 Activity
The 284T variant of POR had only 43.8% of the WT activity 
in CYP3A5 assay with P values below 0.001 in Student’s t-test, 
indicating statistically significant differences (Figure 8). This 
was different from the results obtained for the CYP3A4 activity 
assays, indicating there are differences in the interaction 
of POR with these two closely related cytochrome P450 
proteins. The effect of R550W variation in POR on CYP3A5 
was not as strong as in case of CYP3A4 activity, but the loss 
of activity was still more than 50%, indicating a reduced 
capacity of drug metabolism reactions mediated by CYP3A5. 
CYP3A5 is involved in the metabolism of tacrolimus, an 
immunosuppressant drug used during organ transplants 
which has a narrow therapeutic index.
DISCUSSION
In early reports, the effects of POR variants on drug-metabolizing 
cytochrome P450 enzymes has received less attention compared 
to effects on steroid metabolism (Scott et al., 2007; Agrawal et al., 
2008b; Gomes et al., 2008; Huang et al., 2008b; Miller, 2012; 
Sahakitrungruang et al., 2009; Fukami, 2010). The cytochrome 
P450 subfamily 3A is the most versatile among all P450 
enzymes and accounts for the metabolism of a large number of 
xenobiotics and pharmaceutical compounds. Cytochrome P450 
3A4 (CYP3A4) is the principal hepatic enzyme that metabolizes 
a large percentage of drugs and endogenous substrates (Nicolo 
et al., 2010; Klein and Zanger, 2013; Meyer et al., 2013; Zanger and 
Schwab, 2013). CYP3A5 also has a significant role in xenobiotic 
metabolism in extrahepatic tissues like intestine and gut. The 
cytochrome P450 subfamily 2C is the second most relevant class 
FIGURE 2 | Cytochrome c, MTT, and Ferricyanide reduction assay with WT and 
POR-P284T. (A) Cytochrome c, (B) MTT and (C) ferricyanide reduction assays 
were performed with the WT and POR-P284T variant. Kinetic assays were 
performed by monitoring the changes in absorbance at 550 nm for cytochrome 
c, 610 nm for MTT, and 420 nm for ferricyanide reduction. Data were fitted to 
the Michaelis-Menten kinetics model and analyzed using GraphPad Prism. The 
calculated Km and Vmax values are presented in Table 1.
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of P450 proteins, and CYP2C9 and CYP2C19 are major drug-
metabolizing enzymes.
Our result shows that mutations in POR can affect different 
activities of POR to varying extents, and some cytochrome 
P450 proteins are affected more than others. Also, there may 
be differences due to different allelic variations of cytochrome 
P450 proteins. The effects of different cytochrome P450 isoforms 
on the impact of POR activities has not been studied in detail. 
One study (Subramanian et al., 2012) tested different alleles of 
CYP2C9 (CYP2C9.1, CYP2C9.2, and CYP2C9.3) with a small 
number of POR variants but patterns were similar for all isoforms 
of CYP2C9 (Subramanian et al., 2012).
POR mutations leading to the significant loss of FAD/FMN 
co-factors hurt all redox partner activities (Marohnic et al., 2006; 
Marohnic et al., 2010; Nicolo et al., 2010). However, in most 
other cases, the effects of POR mutations on activities of the 
individual redox partner could be variable (Pandey and Sproll, 
2014; Parween et al., 2016; Flück and Pandey, 2017; Udhane 
et al., 2017; Flück and Pandey, 2019). For the mutation P284T, we 
observed a small loss of cofactor binding, which could be due to 
overall protein stability changes due to the location of the P284 
residue near the hinge region of POR that joins FMN binding 
domain with the FAD-binding domain. However, the activity of 
ferricyanide reduction, which represents direct electron transport 
through FAD without the involvement of FMN indicates that 
this loss of FAD did not severely reduce the overall quality of the 
protein. Cytochrome c reduction that involves protein-protein 
interaction and MTT reduction, which a dual electron transfer 
system through FMN showed loss of activities.
The location of the amino acid P284 in the hinge region 
indicated a potential impact on protein conformation and 
domain movements which may change protein-protein 
interaction, which may differ based on which redox partner is 
FIGURE 3 | Flavin content of POR-WT and POR-P284T variant. Flavin content of the POR proteins was analyzed by boiling the proteins under selective pH 
conditions. Relative fluorescence unit (RFU) of the flavins released from the POR variants measured at (A) pH 2.6 (FAD or F2.6) and (B) pH 7.7 (FMN or F7.7) are 
shown. The RFU of POR-WT was fixed as a hundred percent. Data are shown as mean ± SEM of three independent replicates. Asterisks (**p < 0.01; ***p < 0.001) 
indicates significance based on students t-test.
FIGURE 4 | Enzymatic activity of CYP19A1 supported by POR-WT and 
POR-P284T variant. Bacterially expressed, purified, recombinant CYP19A1, 
and the enriched bacterial membranes containing POR proteins were mixed, 
and their activity to convert [3H] labeled androstenedione to estrone was 
tested by the tritiated water release assay. Data were analyzed using the 
Michaelis-Menten kinetics with GraphPad Prism. The calculated Km and 
Vmax values are shown in Table 1. Data are shown as mean ± SEM (n = 2).
FIGURE 5 | Activity of cytochrome P450 CYP2C9 supported by POR-WT and 
POR-P284T variant. Assay of CYP2C9 activity was performed to compare 
POR-WT and POR-P284T by using 20 µM BOMCC as a substrate. Activity 
with the WT POR was fixed as a hundred percent, and results are given as a 
percentage of WT activity. Data are shown as mean ± SEM of two experiments 
done in triplicates. ***p < 0.001 indicates significance based on students t-test.
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being tested. To study the role of amino acid P284 in POR on 
protein function and electron transfer in POR, we tested POR-
P284T, a naturally identified mutation, with several different 
cytochrome P450 proteins. The CYP19A1 activity requires 
the transfer of three pairs of electrons, and therefore, is more 
susceptible to change in protein interaction with POR (Pandey 
et al., 2007; Flück and Pandey, 2017). A severe loss of CYP19A1 
activity due to P284T mutation (9% of WT activity) indicated a 
significant effect on interaction with POR. In the case of drug-
metabolizing cytochrome P450s, CYP2C9 and CYP3A4 lost 
more than 75% of activities while CYP2C19 and CYP3A5 lost 
more than 50% of the WT POR activity due to P284T mutation 
in POR.
On the other hand, there was no effect on the reduction of 
ferricyanide, a small molecule that can be reduced by direct 
electron transfer from FAD. This observation, together with loss 
of activity observed for reduction of MTT and P450 enzymes like 
CYP19A1, indicates that electron transfer from FAD to FMN is 
affected by changes in hinge region caused by P284T mutation. 
Taken together, these results indicate variability in interaction 
with different cytochrome P450s due to P284T mutation in POR. 
These results further underscore the fact that effects of POR 
mutations can be quite variable for different redox partners and 
mutations in POR require detailed characterization with different 
partner proteins and small molecule substrates to understand the 
biochemical consequences of individual POR mutations. These 
results also reinforce the idea that the hinge region of POR not 
only influences electron transfer within POR from FAD to FMN 
but also regulates the interaction of POR with different redox 
partners. In particular, we have shown here that a mutation in 
the hinge region of POR, P284T, changes the activity of a steroid 
metabolizing cytochrome P450 enzyme (aromatase) and several 
drug-metabolizing P450 enzymes.
Therefore, biochemical analysis using recombinant proteins is 
necessary to confirm the damaging effects of mutations with each 
redox partner separately (Parween et al., 2016; Udhane et al., 
2017; Flück and Pandey, 2019). Several cytochrome P450 proteins 
for which POR is the redox partner, still have uncharacterized 
activities and their physiological roles are not defined. These 
other partners of POR could also influence the metabolic profiles 
of patients with PORD. Preliminary computational docking 
and functional analysis suggest that the loss of activity caused 
by some POR variants may be reversed by the introduction of 
external FMN (Nicolo et al., 2010) or FAD (Marohnic et al., 
2006). However, the effect of flavin treatment in PORD needs to 
be tested in a clinical setting.
FIGURE 6 | Activity of cytochrome P450 CYP2C19 supported by POR-WT 
and POR-P284T variant. Assay of CYP2C19 activity was performed to 
compare POR-WT and POR-P284T by using 20 µM EOMCC as a substrate. 
Activity with the WT POR was fixed as a hundred percent, and results are 
given as a percentage of WT activity. Data are shown as mean ± SEM of two 
experiments done in triplicates. ***p < 0.001 indicates significance based on 
students t-test.
FIGURE 7 | Activity of cytochrome P450 CYP3A4 supported by POR-WT 
and POR-P284T variant. Assay of CYP3A4 activity was performed to 
compare POR-WT and POR-P284T by using 20 µM BOMCC as a substrate. 
Activity with the WT POR was fixed as a hundred percent, and results are 
given as a percentage of WT activity. Data are shown as mean ± SEM of 
three independent replicates. ***p < 0.001 indicates significance based on 
students t-test.
FIGURE 8 | Activity of cytochrome P450 CYP3A5 supported by POR-WT and 
POR-P284T variant. Assay of CYP3A5 activity was performed to compare 
POR-WT and POR-P284T by using BOMCC as a substrate. Activity with the 
WT POR was fixed as a hundred percent, and results are given as a percentage 
of WT activity. Data are shown as mean ± SEM of two experiments done in 
triplicates. ***p < 0.001 indicates significance based on students t-test.
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